Found in Translation: The Utility of C. elegans Alpha-Synuclein Models of Parkinson's Disease

被引:44
|
作者
Gaeta, Anthony L. [1 ]
Caldwell, Kim A. [1 ,2 ,3 ]
Caldwell, Guy A. [1 ,2 ,3 ]
机构
[1] Univ Alabama, Dept Biol Sci, Tuscaloosa, AL 35487 USA
[2] Univ Alabama Birmingham, Sch Med, Nathan Shock Ctr Excellence Basic Biol Aging, Ctr Neurodegenerat & Expt Therapeut,Dept Neurol, Birmingham, AL 35492 USA
[3] Univ Alabama Birmingham, Sch Med, Nathan Shock Ctr Excellence Basic Biol Aging, Ctr Neurodegenerat & Expt Therapeut,Dept Neurobio, Birmingham, AL 35492 USA
基金
美国国家卫生研究院;
关键词
alpha-synuclein; Parkinson; C; elegans; neurodegeneration; dopamine; CAENORHABDITIS-ELEGANS; DOPAMINERGIC NEURODEGENERATION; LEWY BODIES; IDENTIFICATION; HUNTINGTIN; MUTATIONS; OLIGOMERS; GERMLINE; TOXICITY; NETWORK;
D O I
10.3390/brainsci9040073
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkinson's Disease (PD) is the second-most common neurodegenerative disease in the world, yet the fundamental and underlying causes of the disease are largely unknown, and treatments remain sparse and impotent. Several biological systems have been employed to model the disease but the nematode roundworm Caenorhabditis elegans (C. elegans) shows unique promise among these to disinter the elusive factors that may prevent, halt, and/or reverse PD phenotypes. Some of the most salient of these C. elegans models of PD are those that position the misfolding-prone protein alpha-synuclein (-syn), a hallmark pathological component of PD, as the primary target for scientific interrogation. By transgenic expression of human -syn in different tissues, including dopamine neurons and muscle cells, the primary cellular phenotypes of PD in humans have been recapitulated in these C. elegans models and have already uncovered multifarious genetic factors and chemical compounds that attenuate dopaminergic neurodegeneration. This review describes the paramount discoveries obtained through the application of different -syn models of PD in C. elegans and highlights their established utility and respective promise to successfully uncover new conserved genetic modifiers, functional mechanisms, therapeutic targets and molecular leads for PD with the potential to translate to humans.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Modeling Parkinson's Disease With the Alpha-Synuclein Protein
    Gomez-Benito, Monica
    Granado, Noelia
    Garcia-Sanz, Patricia
    Michel, Anne
    Dumoulin, Mireille
    Moratalla, Rosario
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [22] Lipids and alpha-synuclein aggregation in Parkinson's disease
    Broersen, K.
    Davletov, B.
    MOVEMENT DISORDERS, 2007, 22 (12) : VI - VI
  • [23] Familial Parkinson's disease - The awakening of alpha-synuclein
    Goedert, M
    NATURE, 1997, 388 (6639) : 232 - 233
  • [24] Sumoylation of alpha-synuclein in the pathogenesis of parkinson's disease
    Engelender, S.
    JOURNAL OF NEUROCHEMISTRY, 2019, 150 : 48 - 48
  • [25] Autoantibodies to alpha-synuclein in inherited Parkinson's disease
    Papachroni, Katerina K.
    Ninkina, Natalia
    Papapanagiotou, Angeliki
    Hadjigeorgiou, Georgios M.
    Xiromerisiou, Georgia
    Papadimitriou, Alexandros
    Kalofoutis, Anastasios
    Buchman, Vladimir L.
    JOURNAL OF NEUROCHEMISTRY, 2007, 101 (03) : 749 - 756
  • [26] A Characterization of Misfolded Alpha-Synuclein in Parkinson's Disease
    Shannon, Daniel
    Bugada, John-Paul
    Collins, Ethan
    Fischer, Ellie
    Hellard, Delaney
    Hoffman, Trevor
    Kellogg, Nick
    Peters, Kyle
    Poetker, Garret
    Young, Logan
    Diao, JiaJie
    FASEB JOURNAL, 2020, 34
  • [27] Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease
    Dolgacheva L.P.
    Fedotova E.I.
    Abramov A.Y.
    Berezhnov A.V.
    Biochemistry (Moscow), Supplement Series A: Membrane and Cell Biology, 2018, 12 (1) : 10 - 19
  • [28] Alpha-synuclein and presynaptic functionImplications for Parkinson’s disease
    Simon Lykkebo
    Poul Henning Jensen
    NeuroMolecular Medicine, 2002, 2 : 115 - 129
  • [29] Role of alpha-synuclein and tau in Parkinson's disease
    Trojanowski, JQ
    MOVEMENT DISORDERS, 2004, 19 : S2 - S2
  • [30] Targeting Alpha-Synuclein for the Treatment of Parkinson's Disease
    Rohn, Troy T.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2012, 11 (02) : 174 - 179